Abstract
In The Lancet Haematology, Steven Le Gouill and colleagues1 describe a phase 2 trial of obinatuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin) as induction therapy before autologous stem-cell transplantation for patients with mantle cell lymphoma. The trial evaluated minimal residual disease negativity in bone marrow by quantitative PCR (qPCR) after induction chemotherapy and before autologous transplantation. Positive qPCR at an early timepoint could be predictive of a poor outcome with standard autologous transplantation and might allow high-risk patients to be directed to alternative therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
